DPP-4 inhibitors × glycemic control

TrialJournal of diabetes investigation2017

Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes.

R Ravi Shankar et al.PubMed ↗Full text ↗Publisher ↗

  • Sitagliptin 100 mg once dailylooks good hereLower 2-h post-meal glucose, no range given.No ranges given.

What the trial testedas reported · 467 people · 2017

No range given

Reported lower 2-h post-meal glucose, no range given

−26.5mg/dL

sitagliptin 100 mg once daily vs placebo

As reported

difference −26.5 mg/dL, no interval

Who was studied, and how

467people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

sitagliptin 100 mg once daily
placebo

Reported lower 2-h post-meal glucose, no range given−26.5

randomised

the abstract, start to end

0.001) reduced 2-h post-meal glucose by 26.5 mg/dL (1.5 mmol/L) relative to

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
2-h post-meal glucosesitagliptin 100 mg once daily vs placebo
−26.5
DPP-4 inhibitorsGlycemic control

DPP-4 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.820.82 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

11 papers cite it

2017
2018
2019
2020
2021
2022
2023
2024
2025
this papertrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 27740719